Abstract
Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin.
Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020.
Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors.
Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.
Keywords: Concentrated insulin U-500, pharmacokinetics, pharmacodynamics, efficacy, safety, insulin.
Current Diabetes Reviews
Title:Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements
Volume: 17 Issue: 1
Author(s): Nasser Mikhail*
Affiliation:
- Department of Medicine, Endocrinology Division, Olive View-UCLA Medical Center, 14445 Olive View Dr. Sylmar, 91342,United States
Keywords: Concentrated insulin U-500, pharmacokinetics, pharmacodynamics, efficacy, safety, insulin.
Abstract:
Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin.
Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020.
Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors.
Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.
Export Options
About this article
Cite this article as:
Mikhail Nasser *, Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements, Current Diabetes Reviews 2021; 17 (1) . https://dx.doi.org/10.2174/1573399816666200408084614
DOI https://dx.doi.org/10.2174/1573399816666200408084614 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Current Progress of Lipid Analysis in Metabolic Diseases by Mass Spectrometry Methods
Current Medicinal Chemistry Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry Current Views on Dopaminergic Drugs Affecting Glucose Homeostasis
Current Diabetes Reviews Microcirculation in Hypertension: An Update on Clinical Significance and Therapy
Current Vascular Pharmacology Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) β-arrestin-Biased Agonism at the Parathyroid Hormone Receptor Uncouples Bone Formation from Bone Resorption
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Biomonitoring of Endocrine Disrupting Chemicals by HPLC Methods
Current Analytical Chemistry Genetics of Cholesterol and Lipoprotein Metabolism
Recent Patents on Cardiovascular Drug Discovery Protein Modification by β-N-Acetyl Glucosamine (O-GlcNAc) in Insulin Signaling and Insulin Resistance
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Preeclampsia Prediction in Type 1 Diabetes and Diurnal Blood Pressure Methodology
Current Hypertension Reviews Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Subject Index to Volume 10
Current Medicinal Chemistry ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design Platelets and Atherothrombosis: Causes, Targets and Treatments for Thrombosis
Current Medicinal Chemistry Assessment of Antihyperglycemic Effect and Acute Toxicity of the Aqueous <i>Scorzonera undulata</i> Extract in Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy
Current Topics in Medicinal Chemistry Clinical Issues Encountered in the Refeeding of the Patient with Anorexia Nervosa
Current Nutrition & Food Science Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)